Baird Raises Alignment Healthcare Target to $28, Sees 163% Upside to $59
Baird lifted Alignment Healthcare’s price target to $28 from $22 and now projects shares could climb to $59, implying 163% upside from current levels. CEO John Kao sold 180,000 shares on February 10 for $3.68 million at a weighted-average price of $20.49 under a Rule 10b5-1 plan.
1. Baird Raises Price Target
Baird updated its financial model and increased Alignment Healthcare’s price target to $28 from $22, projecting shares could reach $59, which represents a 163% increase from current levels.
2. CEO Stock Sale Details
CEO John E. Kao executed a Rule 10b5-1 plan sale on February 10, disposing of 180,000 shares at a weighted-average price of $20.49 for a total of approximately $3.68 million.
3. Remaining Ownership and Performance
Following the sale, Kao retains indirect ownership of over 2.6 million shares through a trust and personal ownership of more than 1.5 million shares, while the stock has gained 21.7% over the past six months.
4. Profitability and Outlook
Despite a lack of profitability over the last 12 months, analysts forecast FY2025 EPS of $0.23 for the company, which is due to announce fourth-quarter results on February 26, 2026.